Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

NCT02879318 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

180

Enrollment

NETWORK

Sponsor class

Conditions

Pancreatic Adenocarcinoma

Interventions

DRUG: Gemcitabine
DRUG: Nab-paclitaxel
DRUG: Durvalumab
DRUG: Tremelimumab

Sponsor

Canadian Cancer Trials Group

Collaborators

[object Object]